Roche and Genentech reported more good news for their drug Avastin as it demonstrated positive results in a phase III trial for patients with advanced ovarian cancer. See more in WSJ.
Kinex reported that it is entering phase II trials for KX2-391for treatment of bone metastatic, castrate resistant, prostate cancer (CRPC). See details in Medical News Today.
Shire also reported good news when it received Fast Track Status from the FDA on its BLA for Replagal (agalsidase alfa) for the treatment of Fabry's disease. See more in RTT News.
Posted by Bruce Lehr Feb 26, 2010.
Comments